Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Tongue Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Lung Neoplasms 1

Interventions

Docetaxel 7pembrolizumab 3Trastuzumab 3Radiotherapy 3Paclitaxel 3Fluorodeoxyglucose F18 3Erlotinib Hydrochloride 3Cisplatin 3Vorinostat 2Taxes 2SS1(dsFv)PE38 2Polymerase Chain Reaction 2Magnetic Resonance Spectroscopy 2Immunohistochemistry 2Gene Expression Profiling 2Filgrastim 2Cetuximab 2Biopsy 2zanidatamab 1vandetanib 1trastuzumab deruxtecan 1tipifarnib 1tanespimycin 1talactoferrin alfa 1spartalizumab 1sargramostim 1pertuzumab 1neratinib 1larotrectinib 1fluoromisonidazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Salivary Gland Neoplasms × talactoferrin alfa × Thoracic × Clear all
NCT01528137 2016-08-02

Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer

Stanford University

Phase 1 Terminated
4 enrolled
Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Salivary Gland Neoplasms, Tongue Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡